Evidence map›Paper›PMID 27313716›Full record

ArticleOncology letters2016

miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer.

Xuexiang Liu, Jinwan Li, Fengxian Qin, Shengming Dai

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. mEpigenetics · 2022
    Article
  13. Review
  14. Review
  15. Angioregulatory microRNAs in breast cancerJournal of advanced research · 2022
    Review
  16. Article
  17. miR-152 Regulates Bovine Myoblast Proliferation by Targeting KLF6.Animals : an open access journal from MDPI · 2021
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xuexiang LiuDepartment of Laboratory Science, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China.
Jinwan LiDepartment of Laboratory Science, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China.
Fengxian QinDepartment of Laboratory Science, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China.
Shengming DaiDepartment of Laboratory Science, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China.
Fourth Affiliated Hospital of Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs or miRs) are endogenous translation repressors of protein-coding genes that act by binding to the 3'-untranslated region of their target genes, and may contribute to tumorigenesis by functioning as oncogenes or tumor suppressor genes. miR-152, a member of the miR-148/152 family, is aberrantly expressed in various diseases, including various types of cancer. A growing body of evidence has demonstrated that miR-152 may act as a tumor suppressor gene by regulating its target genes, which are associated with cell proliferation, migration and invasion in human cancer. In the present review, the gene structure and functions of miR-152 are discussed, and in particular, its regulatory mechanism, experimentally validated targets and tumor suppressor role in cancer, are highlighted.

Indexed as

human cancerhypermethylationmiR-152tumor suppressor

Identifiers

PMID27313716
PMCPMC4888271
OpenAlexW2344548537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.